EMMA (Emmaus Life Sciences) Preferred Dividends: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Emmaus Life Sciences Preferred Dividends?

Emmaus Life Sciences EMMA +1.56% Preferred Dividends is $0.00 Mil as of Jun. 2026. The stock has 5 warning signs investors should review.

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Emmaus Life Sciences's preferred dividends for the three months ended in Jun. 2026 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil.

Emmaus Life Sciences  (OTCPK:EMMA) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences Preferred Dividends Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences Preferred Dividends Chart

Emmaus Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Preferred Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Emmaus Life Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Preferred Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Emmaus Life Sciences Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Frequently Asked Questions Learn more about Preferred Dividends →
What does a Preferred Dividends of $0.00 Mil mean?
Emmaus Life Sciences (EMMA) has a Preferred Dividends of $0.00 Mil as of Jun. 2026. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on Emmaus Life Sciences and its competitors.
Is Emmaus Life Sciences' Preferred Dividends too high?
Emmaus Life Sciences' current Preferred Dividends is $0.00 Mil.
How does Emmaus Life Sciences' Preferred Dividends compare to PCSA and LIMN?
Emmaus Life Sciences' Preferred Dividends of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Dividends for a Biotechnology company?
A good Preferred Dividends depends on the Biotechnology industry context. However, Preferred Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Dividends mean?
A high Preferred Dividends can signal that a stock is expensive relative to its fundamentals. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current Preferred Dividends is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.07 — trading 550% above its estimated fair value. The current Preferred Dividends is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Dividends calculated?
Preferred Dividends is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Preferred Dividends is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc. is a commercial-stage biopharmaceutical company focused on the treatment of sickle cell disease and other orphan diseases. Its lead product, Endari (prescription-grade L-glutamine oral powder), is approved in the United States to reduce acute complications of sickle cell disease in adult and pediatric patients aged five and older. The company markets and sells Endari directly in the U.S., where it is reimbursed by Medicare, Medicaid programs in all states, and many commercial payors. Emmaus also pursues international distribution and licensing arrangements, including in the Middle East and other regions, and conducts research on additional uses of L-glutamine and related therapies. Revenue is generated primarily from Endari product sales and, to a lesser extent, licensing and collaboration agreements.